You can buy or sell IDRA and other stocks, options, ETFs, and crypto commission-free!
Idera Pharmaceuticals, Inc. Common Stock, also called Idera Pharmaceuticals, is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. Read More The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Cambridge, MA.
52 Week High
52 Week Low
Yahoo FinanceMay 10
Idera Pharmaceuticals, Inc. Shares March Higher, Can It Continue?
As of late, it has definitely been a great time to be an investor in Idera Pharmaceuticals, Inc. (IDRA). As of late, it has definitely been a great time to be an investor in Idera Pharmaceuticals, Inc. IDRA. The stock has moved higher by 25% in the past month, while it is also above its 20 Day SMA too. This combination of strong price performance and favorable technical, could suggest that the stock may be on the right path. We certainly think that this might be the case, particularly if you consider IDRA...
Yahoo FinanceMay 2
Idera Pharmaceuticals (IDRA) Reports Q1 Loss, Lags Revenue Estimates
Idera (IDRA) delivered earnings and revenue surprises of 13.04% and -100.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Yahoo FinanceMay 1
Will Idera Pharmaceuticals (IDRA) Report Negative Q1 Earnings? What You Should Know
Wall Street expects a year-over-year increase in earnings on lower revenues when Idera Pharmaceuticals (IDRA) reports results for the quarter ended March 2019. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.
Expected Aug 1, After Hours